AMENDMENTS TO THE CLAIMS

1. - 2. (Canceled)

3. (Currently amended) A method for administering cyclosporin into cerebrospinal fluid or
cerebrospinal fluid spaces of a patient, which comprises:
providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically
acceptable carrier, and
administering said cyclosporin and DMSO sterile injectable solution by injection into the a
cerebrospinal fluid or cerebrospinal fluid spaces of said patient.
 wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total
composition, and wherein DMSO is present in at least 80% by weight of the total
composition.
wherein said cyclosporin is present in an amount of from 0.1 to 90% by weight of the total
composition.
4. (Currently Amended) A method for administering a sterile injectable solution of cyclosporin
to a patient, which <u>comprises</u> compromises:
providing a sterile injectable solution of cyclosporin dissolved in DMSO in a pharmaceutically
annutable anning and
acceptable carrier, and
acceptable carrier, and —_administering said sterile injectable solution of cyclosporin and DMSO to said patient by
·
administering said sterile injectable solution of cyclosporin and DMSO to said patient by
administering said sterile injectable solution of cyclosporin and DMSO to said patient by intravestibular injection, into or adjacent to the brain, or into or adjacent to the spinal cord of
administering said sterile injectable solution of cyclosporin and DMSO to said patient by intravestibular injection, into or adjacent to the brain, or into or adjacent to the spinal cord of said patient,
 administering said sterile injectable solution of cyclosporin and DMSO to said patient by intravestibular injection, into or adjacent to the brain, or into or adjacent to the spinal cord of said patient, wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total
 administering said sterile injectable solution of cyclosporin and DMSO to said patient by intravestibular injection, into or adjacent to the brain, or into or adjacent to the spinal cord of said patient, wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present in at least 80% by weight of the total

App. No. 09/674,092 Docket No.: 0030-0200P

5. (Currently Amended) A method for administering cyclosponin by injection method for administering cyclosponin by injection method for
intravenous, intra-arterial or intraparenchymal injection, into a patient, which
comprises compromises:
providing a sterile injectable solution of cyclosporin dissolved in DMSO according to claim 1
in a pharmaceutically acceptable carrier, and
$\underline{\hspace{0.3cm}}$ administering said sterile injectable solution of cyclosporin and DMSO by injection into \underline{an}
intravenous, intra-arterial or intraparenchymal spaces of said patient,
wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition,
and wherein DMSO is present at least 80% by weight in the composition.
6. (Currently Amended) A method for administering cyclosporin inhalationally or nasally to a
patient, which-compromises comprises:
providing the cyclosporin dissolved in DMSO according to claim 1 in a pharmaceutically

7. (**Currently Amended**) The method of claim 3, 4, 5 or 6, wherein the cyclosporin is cyclosporin A or a salt thereof.

___administering said cyclosporin and DMSO solution inhalationally or nasally to said patient, wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition,

and wherein DMSO is present at least 80% by weight in the composition.

8. - 9. (Canceled)

acceptable-solution carrier, and

- 10. (**Currently amended**) The method according to claim 3 wherein the administration of a sterile injectable solution of cyclosporin into <u>said</u> cerebrospinal fluid <u>spaces</u> is intraventricular or intrathecal.
- 11. (**Currently Amended**) A method for treating Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, HIV neuropathy, Guillain-Barré syndrome, neural transplantation, neural xenotransplantation, stroke, brain hemorrhage, brain and spine trauma, ionizing radiation, neurotoxicity of vestibular structures, or retinal detachment, which comprises: administering a sterile injectable solution of cyclosporin dissolved in DMSO

according to the method of claim 43, 4, 5 or 6 in a pharmaceutically acceptable carrier to said patient.

12. (**Currently Amended**) A method for inducing systemic immunosuppression in a patient of transplantation or autoimmune disease, which comprises: administering a sterile injectable solution of cyclosporin and DMSO according to the method of claim 3, 4, 5 or 6 4 to said patient.

13. - 20. (Canceled)

21. (**Currently amended**) The method according to claim 3, wherein the sterile injectable solution of cyclosporin dissolved in DMSO comprises a cyclosporin dissolved in dimethylsulfoxide (DMSO), wherein the concentration of cyclosporin is from 0.1% to 20% by weight of the total composition, and wherein DMSO is present <u>in</u> at least 80% by weight <u>in-of</u> the total composition.

22. - 23. (Canceled)

- 24. (**Currently amended**) The method of claim 3, 4, 5 or 6 wherein a dose of from 50 to 150 mg/ 0.0001 to 200 mg/kg/day of cyclosporin is administered.
- 25. (**Currently amended**) The method of claim <u>3, 4, 5 or 6</u>, wherein a dose of from <u>50 to 150 5</u> to <u>5000 mg</u>/day of cyclosporin is administered.

4

26. (Canceled)